Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Aug;26(4):471-92.
doi: 10.1023/a:1021068202606.

Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile

Affiliations
Clinical Trial

Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile

K Park et al. J Pharmacokinet Biopharm. 1998 Aug.

Abstract

A model for the pharmacodynamic effect of a drug (designated only X), and the use of the model to explore optimal input is described. The data analyzed here are from a crossover comparison study of the effect of 4 active treatments, yielding distinct concentration vs. time curves, plus placebo in 32 subjects. The model expresses total effect as the sum of placebo effect and (pure) drug effect. The latter allows for possible tolerance (found) and time effects (not found). Random effects allow interindividual differences to be expressed. Conditioning on the fitted model, a population optimal input profile is designed that obeys certain protocol constraints. The profile minimizes the expectation of a sum of squared differences between target effect and the resulting response over a given time interval. The target is a fixed constant, chosen to be either the individuals' maximum effect level in response to a baseline input regimen used in the study or the maximum effect level for the typical individual in the population in response to this regimen, as predicted from the model. The expectation is taken over the estimated nonparametric distribution of the 32 subjects' random effects. As one goal of early clinical studies of drugs may be to provide a basis for designing an optimal delivery profile (with respect to a specified loss function), we suggest this report as an example of a reasonable way to go about finding such a profile.

PubMed Disclaimer

References

    1. Int J Clin Pharmacol Ther Toxicol. 1982 Dec;20(12):564-75 - PubMed
    1. J Pharmacokinet Biopharm. 1979 Dec;7(6):579-628 - PubMed
    1. J Pharmacokinet Biopharm. 1986 Oct;14(5):523-37 - PubMed
    1. J Pharmacokinet Biopharm. 1995 Dec;23(6):611-34 - PubMed
    1. J Pharmacokinet Biopharm. 1995 Dec;23(6):581-610 - PubMed

Publication types

LinkOut - more resources